EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events

Hannes Helgason, Thjodbjorg Eiriksdottir, Magnus O Ulfarsson, Abhishek Choudhary, Sigrun H Lund, Erna V Ivarsdottir, Grimur Hjorleifsson Eldjarn, Gudmundur Einarsson, Egil Ferkingstad, Kristjan H S Moore, Narimon Honarpour, Thomas Liu und 23 weitere

JAMA · 22.08.2023 · 330 (8) · 725

DOI: 10.1001/jama.2023.13258 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift JAMA, erschienen am 22.08.2023. Verfasst von Hannes Helgason und 34 weiteren Autor:innen. Beteiligte Einrichtung: deCODE genetics/Amgen, Inc, Reykjavik, Iceland. Hauptthemen laut MEDLINE: Atherosclerosis, Proteomics, Cardiovascular Diseases. Die Arbeit wurde bisher 136-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Whether protein risk scores derived from a single plasma sample could be useful for risk assessment for atherosclerotic cardiovascular disease (ASCVD), in conjunction with clinical risk factors and polygenic risk scores, is uncertain.

Objective

To develop protein risk scores for ASCVD risk prediction and compare them to clinical risk factors and polygenic risk scores in primary and secondary event populations. Design, Setting, and Participants The primary analysis was a retrospective study of primary events among 13 540 individuals in Iceland (aged 40-75 years) with proteomics data and no history of major ASCVD events at recruitment (study duration, August 23, 2000 until October 26, 2006; follow-up through 2018). We also analyzed a secondary event population from a randomized, double-blind lipid-lowering clinical trial (2013-2016), consisting of individuals with stable ASCVD receiving statin therapy and for whom proteomic data were available for 6791 individuals. Exposures Protein risk scores (based on 4963 plasma protein levels and developed in a training set in the primary event population); polygenic risk scores for coronary artery disease and stroke; and clinical risk factors that included age, sex, statin use, hypertension treatment, type 2 diabetes, body mass index, and smoking status at the time of plasma sampling. Main Outcomes and Measures Outcomes were composites of myocardial infarction, stroke, and coronary heart disease death or cardiovascular death. Performance was evaluated using Cox survival models and measures of discrimination and reclassification that accounted for the competing risk of non-ASCVD death.

Results

In the primary event population test set (4018 individuals [59.0% women]; 465 events; median follow-up, 15.8 years), the protein risk score had a hazard ratio (HR) of 1.93 per SD (95% CI, 1.75 to 2.13). Addition of protein risk score and polygenic risk scores significantly increased the C index when added to a clinical risk factor model (C index change, 0.022 [95% CI, 0.007 to 0.038]). Addition of the protein risk score alone to a clinical risk factor model also led to a significantly increased C index (difference, 0.014 [95% CI, 0.002 to 0.028]). Among White individuals in the secondary event population (6307 participants; 432 events; median follow-up, 2.2 years), the protein risk score had an HR of 1.62 per SD (95% CI, 1.48 to 1.79) and significantly increased C index when added to a clinical risk factor model (C index change, 0.026 [95% CI, 0.011 to 0.042]). The protein risk score was significantly associated with major adverse cardiovascular events among individuals of African and Asian ancestries in the secondary event population. Conclusions and Relevance A protein risk score was significantly associated with ASCVD events in primary and secondary event populations. When added to clinical risk factors, the protein risk score and polygenic risk score both provided statistically significant but modest improvement in discrimination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisProteomicsCardiovascular DiseasesFemaleHumansMaleDiabetes Mellitus, Type 2Hydroxymethylglutaryl-CoA Reductase InhibitorsRetrospective StudiesStrokeRisk AssessmentAdultMiddle AgedAgedIcelandRandomized Controlled Trials as Topic

Substanzen

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • deCODE genetics/Amgen, Inc, Reykjavik, Iceland.
  • University of Iceland, Reykjavik, Iceland.
  • Amgen, Inc, Thousand Oaks, California.
  • TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Zitieren

APA

Helgason, H., Eiriksdottir, T., Ulfarsson, M. O., Choudhary, A., Lund, S. H., Ivarsdottir, E. V., Hjorleifsson Eldjarn, G., Einarsson, G., Ferkingstad, E., Moore, K. H. S., Honarpour, N., Liu, T., Wang, H., Hucko, T., Sabatine, M. S., Morrow, D. A., Giugliano, R. P., Ostrowski, S. R., Pedersen, O. B., …, & Stefansson, K. (2023). Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events. JAMA, 330(8), 725. https://doi.org/10.1001/jama.2023.13258

Vancouver

Helgason H, Eiriksdottir T, Ulfarsson MO, Choudhary A, Lund SH, Ivarsdottir EV, et al. Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events. JAMA. 2023;330(8):725. doi:10.1001/jama.2023.13258

BibTeX
@article{Helgason2023,
  author = {Helgason, Hannes and Eiriksdottir, Thjodbjorg and Ulfarsson, Magnus O and Choudhary, Abhishek and Lund, Sigrun H and Ivarsdottir, Erna V and Hjorleifsson Eldjarn, Grimur and Einarsson, Gudmundur and Ferkingstad, Egil and Moore, Kristjan H S and Honarpour, Narimon and Liu, Thomas and Wang, Huei and Hucko, Thomas and Sabatine, Marc S and Morrow, David A and Giugliano, Robert P and Ostrowski, Sisse Rye and Pedersen, Ole Birger and Bundgaard, Henning and Erikstrup, Christian and Arnar, David O and Thorgeirsson, Gudmundur and Masson, Gísli and Magnusson, Olafur Th and Saemundsdottir, Jona and Gretarsdottir, Solveig and Steinthorsdottir, Valgerdur and Thorleifsson, Gudmar and Helgadottir, Anna and Sulem, Patrick and Thorsteinsdottir, Unnur and Holm, Hilma and Gudbjartsson, Daniel and Stefansson, Kari},
  title = {Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events},
  journal = {JAMA},
  year = {2023},
  volume = {330},
  number = {8},
  pages = {725},
  doi = {10.1001/jama.2023.13258}
}
Kostenlos starten →